Feasibility and Tolerability of Anlotinib Plus PD-1 Inhibitors for Previously-Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study.

Biologics · 2024 · PMC11549916 · PMID 39524378

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Notably, patients who received anlotinib (12 mg) showed a trend for longer PFS than those who received 10 mg anlotinib, although no statistically significant difference was observed (median PFS: 7.0 vs 5.9 months, P =0.117, respectively).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.